HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Amane Tateno Selected Research

blonanserin

5/2022Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.
5/2021Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients.
1/2021Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
1/2018Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
4/2013Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Amane Tateno Research Topics

Disease

7Schizophrenia (Dementia Praecox)
05/2022 - 08/2010
4Alzheimer Disease (Alzheimer's Disease)
01/2017 - 03/2007
3Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
11/2021 - 04/2014
3Major Depressive Disorder (Major Depressive Disorders)
12/2019 - 06/2013
2Narcolepsy
11/2021 - 05/2014
2Anhedonia
08/2020 - 08/2014
2Pain (Aches)
09/2018 - 06/2014
2Atrophy
07/2015 - 05/2015
2Cognitive Dysfunction
07/2015 - 05/2015
1Treatment-Resistant Depressive Disorder
11/2021
1Parkinson Disease (Parkinson's Disease)
01/2021
1Obesity
12/2019
1Substance-Related Disorders (Drug Abuse)
09/2018
1Mental Disorders (Mental Disorder)
08/2014
1Dementia (Dementias)
10/2013
1Hyperprolactinemia
04/2013
1Traumatic Brain Injuries (Traumatic Brain Injury)
01/2004
1Anxiety Disorders (Anxiety Disorder)
05/2003
1Stroke (Strokes)
05/2003

Drug/Important Bio-Agent (IBA)

5blonanserinIBA
05/2022 - 04/2013
3Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
05/2022 - 04/2013
3Modafinil (Provigil)FDA Link
11/2021 - 05/2014
3Dopamine (Intropin)FDA LinkGeneric
08/2020 - 04/2013
3Amyloid beta-PeptidesIBA
01/2017 - 05/2015
3Amyloid (Amyloid Fibrils)IBA
07/2015 - 01/2014
2Antipsychotic Agents (Antipsychotics)IBA
05/2022 - 04/2013
2Tramadol (K315)FDA LinkGeneric
09/2018 - 06/2014
2Biomarkers (Surrogate Marker)IBA
01/2017 - 05/2015
2florbetapirIBA
07/2015 - 05/2015
2Serotonin (5 Hydroxytryptamine)IBA
06/2014 - 06/2013
2Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA
04/2014 - 06/2013
2Nortriptyline (Aventyl)FDA LinkGeneric
04/2014 - 05/2003
2Risperidone (Risperdal Consta)FDA LinkGeneric
10/2013 - 04/2013
15-HT1B Serotonin ReceptorIBA
11/2021
1KetamineFDA LinkGeneric
11/2021
1naxagolideIBA
05/2021
1Dopamine D3 ReceptorsIBA
05/2021
12- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA
01/2021
1TabletsIBA
01/2021
1Bupropion (Wellbutrin)FDA LinkGeneric
12/2019
1Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric
01/2019
1Therapeutic UsesIBA
01/2019
1Pharmaceutical PreparationsIBA
08/2014
1Opioid Receptors (Opioid Receptor)IBA
06/2014
1Norepinephrine (Noradrenaline)FDA LinkGeneric
06/2014
1Wakefulness-Promoting AgentsIBA
05/2014
1Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
05/2014
1Yi-Gan SanIBA
10/2013
1Fluvoxamine (Luvox)FDA LinkGeneric
10/2013
1Milnacipran (Ixel)FDA Link
06/2013
1ProlactinIBA
04/2013
1RacloprideIBA
04/2013
1FLB 457IBA
04/2013
1Hormones (Hormone)IBA
01/2013
1GABA-A Receptors (GABA(A) Receptor)IBA
08/2010
1DAA 1106IBA
08/2010
15'-palmitoyl cytarabine (PLAC)IBA
01/2004

Therapy/Procedure

1Transdermal Patch
05/2022
1Activities of Daily Living (ADL)
07/2015
1Gamma Cameras (Gamma Camera)
03/2007